1. Advanced Hepatocellular and Renal Cell Carcinomas: Updated Data in Specific Patient Populations Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) May 30-June 3, 2008 Chicago, Illinois

6. Responses to Sorafenib According to Resistance IM-RES (n=6) IM/SU-RES (n=23) Overall (n=29) CR0 (0%) PR1 (17%)3 (13%)4 (14%) SD3 (50%)15 (65%)18 (62%) Disease control: CR+PR+SD 4 (67%)18 (78%)22 (76%) Adapted from Wiebe et al. ASCO 2008, abstract 10502.

7. Toxicities Developed After Sorafenib Treatment (n=29) Grade 3 (% patients) Grade 4 (% patients) Hypertension24- Hand-foot24- Rash17- Diarrhea10- Fatigue7- Hemorrhage7- Thrombosis-3 Perforation3- Anemia3- Adapted from Wiebe et al. ASCO 2008, abstract 10502.

8. Cardiac-related Grade ≥3 Adverse Events Adverse events (%)≥65 years (n=1131) <65 years (n=1361) Hypertension55 Cardiac ischemia11 Hypotension10.3 Cardiac arrhythmia10.2 Adapted from Bukowski et al. ASCO 2008, abstract 5045.

9. Cost-effectiveness Results First-line treatmentBest supportive care Sorafenib Life-years gained (discounted) Mean*1.061.59 Standard deviation0.100.18 Total costs (discounted) Mean*$8,161$41,782 Standard deviation$1,408$3,292 Incermental LYG0.53 Incermental costs$33,621 Incermental cost per LYG$63,436 *Probabilistic mean Adapted from Muzbek et al. ASCO 2008, abstract 6527.

10. RECIST Response by ECOG PS Percentage of patients PS 0PS 1-2 sorafenib (n=161) Placebo (n=164) Sorafenib (n=138) Placebo (n=139) ORR (CR + PR)2.50.62.20.7 SD77.670.162.364.0 PD13.725.623.222.3 Not assessable6.23.712.313.0 DCR46.636.039.926.6 Adapted from Raoul et al. ASCO 2008, abstract 4587.

11. SHARP: Baseline Patient Characteristics MVI/EHS present (n=421) MVI/EHS absent (n=181) Characteristics Sorafenib (n=209) Placebo (n=90) Sorafenib (n=90) Placebo (n=91) Median age (range), years66 (21-84)68 (21-82)67 (21-89)70 (39-86) Male/female, %88/12 86/14 ECOG PS, % 0 1-2 51 49 53 47 60 40 56 44 Region (Europe/North/other), % 86/11/387/9/493/4/287/10/3 Etiology, % Viral hepatitis (HBV/HCV) Alcohol/other 18/26 26/30 20/25 24/31 20/37 27/17 13/32 33/22 Child-Pugh class (A/B), %94/599/197/3 BCLC stage (B/C), %0/100 60/4056/44 MVI (yes/no), %52/4858/420/100 EHS (yes/no), %76/2471/290/100 Adapted from Sherman et al. ASCO 2008, abstract 4584.

12. SHARP: RECIST Response Stratified by MVI and/or EHS Percentage of patients MVI and/or EHS presentMVI and/or EHS absent Sorafenib (n=209) Placebo (n=212) Sorafenib (n=90) Placebo (n=91) ORR (CR + PR)2.40.92.20 SD65.662.782.278.0 PD21.527.410.016.5 Not assessable10.59.05.65.5 DCR*41.227.848.940.7 *Disease control rate is defined as the proportion of patients with a best response of CR, PR or SD by RECIST that is maintained for ≥28 days following demonstration of that response. Adapted from Sherman et al. ASCO 2008, abstract 4584.